REPLIGEN CORP Repayments of Convertible Debt
REPLIGEN CORP (RGEN) reported Repayments of Convertible Debt of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-02-26
- REPLIGEN CORP repayments of convertible debt for the quarter ending 2025-12-31 was $0.00.
- REPLIGEN CORP repayments of convertible debt for the quarter ending 2024-12-31 was $0.00.
- REPLIGEN CORP repayments of convertible debt for the quarter ending 2023-12-31 was -$33.00K.
- REPLIGEN CORP repayments of convertible debt for the quarter ending 2023-09-30 was $24.00K.
- REPLIGEN CORP repayments of convertible debt for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- REPLIGEN CORP repayments of convertible debt for fiscal 2024 was $69.94M.
- REPLIGEN CORP repayments of convertible debt for fiscal 2023 was $0.00.
- REPLIGEN CORP repayments of convertible debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month | Repayments of Convertible Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $69.94M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $69.94M 10-Q · filed 2025-11-04 | ||||
| 2023-12-31 | -$33.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-26 | -$9.00K derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 | |
| 2023-09-30 | $24.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $33.00K derived: sum of 2 quarters · filed 2024-11-18 | $33.00K 10-Q/A · filed 2024-11-18 | $15.00K derived: sum of 4 quarters · filed 2025-03-14 | |
| 2023-06-30 | $9.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $9.00K 10-Q/A · filed 2024-11-18 | -$9.00K derived: sum of 3 quarters · filed 2025-03-14 | -$9.00K derived: sum of 4 quarters · filed 2025-03-14 | |
| 2023-03-31 | $0.00 10-Q/A · filed 2024-11-18 | -$18.00K derived: sum of 2 quarters · filed 2025-03-14 | -$18.00K derived: sum of 3 quarters · filed 2025-03-14 | -$6.00K derived: sum of 4 quarters · filed 2025-03-14 | |
| 2022-12-31 | -$18.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | -$18.00K derived: sum of 2 quarters · filed 2025-03-14 | -$6.00K derived: sum of 3 quarters · filed 2025-03-14 | $0.00 10-K · filed 2025-03-14 | $26.00K 10-K · filed 2023-02-22 |
| 2022-09-30 | $0.00 derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18 | $12.00K derived: sum of 2 quarters · filed 2024-11-18 | $18.00K 10-Q/A · filed 2024-11-18 | $30.00K derived: sum of 4 quarters · filed 2024-11-18 | |
| 2022-06-30 | $12.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18 | $18.00K 10-Q/A · filed 2024-11-18 | $30.00K derived: sum of 3 quarters · filed 2024-11-18 | $31.00K derived: sum of 4 quarters · filed 2024-11-18 | |
| 2022-03-31 | $6.00K 10-Q/A · filed 2024-11-18 | $18.00K derived: sum of 2 quarters · filed 2024-11-18 | $19.00K derived: sum of 3 quarters · filed 2024-11-18 | $26.00K derived: sum of 4 quarters · filed 2024-11-18 | |
| 2021-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $13.00K derived: sum of 2 quarters · filed 2023-02-22 | $20.00K derived: sum of 3 quarters · filed 2023-02-22 | $21.00K 10-K · filed 2023-02-22 | |
| 2021-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $8.00K derived: sum of 2 quarters · filed 2022-11-01 | $9.00K 10-Q · filed 2022-11-01 | ||
| 2021-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $8.00K 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | $1.00K 10-Q · filed 2022-04-27 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-22 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $114.97M derived: sum of 2 quarters · filed 2022-02-17 | $114.99M 10-K · filed 2022-02-17 | ||
| 2019-09-30 | $114.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $114.99M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $17.00K 10-Q · filed 2020-07-30 | ||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $0.00 derived: sum of 2 quarters · filed 2021-02-24 | $0.00 derived: sum of 3 quarters · filed 2021-02-24 | $11.00K 10-K · filed 2021-02-24 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $0.00 derived: sum of 2 quarters · filed 2019-10-31 | $11.00K 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $11.00K 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | $11.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |